Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | USP7 | Q93009 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | USP19 | O94966 | 1/20 | 0.39 |
| ▸ | STAT1 | P42224 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11985536 | 0.85 | RAB9A (0.56) | GAAUSP7SMN1; SMN2KDM4ERAB9A | |
| SCHEMBL16983043 | 0.83 | GAA (0.44) | GAAUSP7SMN1; SMN2KDM4ERAB9A | |
| SCHEMBL17770681 | 0.80 | USP7 (0.53) | GAAUSP7KDM4ETDP1LMNA | |
| SCHEMBL25756987 | 0.78 | SMN1; SMN2 (0.52) | USP7SMN1; SMN2KDM4ERAB9ANPC1 | |
| SCHEMBL2993563 | 0.77 | HDAC1 (0.49) | GAAUSP7SMN1; SMN2KDM4EL3MBTL1 | |
| SCHEMBL16983058 | 0.76 | USP7 (0.42) | GAAUSP7SMN1; SMN2KDM4ERAB9A | |
| SCHEMBL3118173 | 0.76 | SMN1; SMN2 (0.69) | GAASMN1; SMN2KDM4ERAB9ANPC1 | |
| SCHEMBL16983034 | 0.75 | NPSR1 (0.52) | USP7SMN1; SMN2KDM4ERAB9ANPC1 | |
| SCHEMBL15265698 | 0.75 | USP19 (0.44) | GAAUSP7SMN1; SMN2RAB9ANPC1 | |
| SCHEMBL2999350 | 0.72 | SMN1; SMN2 (0.67) | SMN1; SMN2KDM4ERAB9ANPC1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12122786-B2 | Inhibitors of cyclic mono- and di-nucleotide phosphodiesterases and the uses thereof | PURDUE RESEARCH FOUNDATION (US) | 2024-10-22 | — | — | US | disclosed |
| US-20220194957-A1 | INHIBITORS OF CYCLIC MONO- AND DI-NUCLEOTIDE PHOSPHODIESTERASES AND THE USES THEREOF | PURDUE RESEARCH FOUNDATION (US) | 2022-06-23 | — | — | US | disclosed |
| US-20100189685-A1 | Antiviral Drugs for Treatment or Prevention of Dengue Infection | SIGA TECHNOLOGIES, INC. | 2010-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100189685-A1 | Antiviral Drugs for Treatment or Prevention of Dengue Infection | EIF2AK2, HAVCR2, SNRPE | GAA 97/4885USP7 3623/4885SMN1; SMN2 509/4885 |
| US-20220194957-A1 | INHIBITORS OF CYCLIC MONO- AND DI-NUCLEOTIDE PHOSPHODIESTERASES AND THE USES THEREOF | CGAS, DTYMK, PDE7A | GAA 907/4885USP7 2017/4885SMN1; SMN2 4328/4885 |
| US-12122786-B2 | Inhibitors of cyclic mono- and di-nucleotide phosphodiesterases and the uses thereof | DTYMK, CGAS, PDE7A | GAA 764/4885USP7 1753/4885SMN1; SMN2 4341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.